Biopharmaceutical company GSK plc (LSE:GSK) (NYSE:GSK) on Wednesday raised its guidance for the full year after reporting strong growth in the second quarter.
Turnover in the three months ended 30 June 2022 amounted to GBP6.9bn, up 19% or 13% at constant exchange rates.
Vaccine sales totalled GBP1.7bn, including a record quarter for the company's shingles vaccine Shingrix which generated GBP731m in sales.
Adjusted operating profit for the second quarter was GBP2.0bn, a year-on-year increase of 22% or 7% at constant exchange rates.
GSK now expects full-year sales to grow by 6% to 8% (previously 5% to 7%), with adjusted operating profit up 13% to 15% (previously 12% to 14%), excluding COVID-19 related revenues.
(USD1=GBP0.83)
Eli Lilly and Company announces dividend for fourth quarter of 2022
Biocorp and Merck KGaA, Darmstadt, Germany Partner on Smart Drug Delivery
BIOCORP and Germany's Merck sign smart drug delivery agreement
Pfizer to supply up to 6 million Paxlovid treatments to Global Fund
AbbVie announces quarterly cash dividend
Common and Affordable Drug Can Drastically Reduce COVID Complications, Study Shows
Moderna sues Pfizer and BioNTech over COVID-19 vaccine patents